Vitamin K2 could be novel therapeutic target for common cardiovascular condition

ba04826b-fcc6-419b-b99f-6604a2724b70articleimage.jpg

23 Nov 2017 --- The European Heart Journal has published a review paper that highlights the potential of vitamin K2 supplementation for calcific aortic valve stenosis (CAVS), a common cardiovascular condition in the aging population where no medical therapy currently exists.

According to researchers, once symptomatic severe CAVS has developed, there is a dismal prognosis without intervention. Currently, the only treatment for (symptomatic) severe CAVS is surgical or trans catheter aortic valve replacement (AVR), but it is an intervention to which not all patients are suited.

While multiple trials have attempted to repurpose commonly used pharmacological interventions to slow CAVS progression, pharmacological interventions have thus far failed to alter the course of CAVS. The review paper notes that studies have demonstrated that statins, widely used for lipid lowering in atherosclerosis and inflammation, have no effect on CAVS progression or clinical outcomes, and might actually exacerbate the condition.

However, the researchers noted promise with vitamin K2, specifically the long-chain menaquinones (MK7), as they are transported efficiently beyond the liver. “Vitamin K supplementation is an attractive option to replenish vascular vitamin K stores to ensure optimal calcification inhibition,” the researchers write.

“Recognizing that medical therapies are proving ineffective, researchers are shining a light on efficacious supplemental alternatives, which leads them to the clinical research that NattoPharma has spearheaded,” says Dr. Hogne Vik, Chief Medical Officer with Norwegian-based NattoPharma ASA, a company targeting vitamin K2 research and development. 

“Specifically, our three-year cardiovascular study in healthy postmenopausal women taking just 180 mcg daily of Vitamin K2 as MK-7 (as MenaQ7) demonstrated a cessation and even regression in arterial stiffness,” Dr. Vik adds. “The relevance of our three-year study has resulted in several studies by the medical community for patients with existing coronary artery calcification, aortic valve calcification, and peripheral artery calcification.”

The review paper concludes: “The pathophysiological mechanisms involved in CAVS initiation and progression are being rapidly elucidated and include inflammation, fibrosis, and calcification. With this advancing knowledge, we have identified novel therapeutic targets like vitamin K and new imaging techniques that can be used to test the efficacy of novel agents and further inform our pathophysiological understanding.”

In an interview with NutritionInsight earlier this year, Eric Anderson, Senior Vice President of Global Marketing and Business Development at NattoPharma, underlined the company’s commitment to supporting research into the benefits of vitamin K. “When we look at vitamin K2 as menaquinone-7, we believe this is everything that is good about the natural products industry,” Anderson said. “Researchers discovered K2, and NattoPharma supported its substantiation.”

“We’re only supplying the active, menaquinone/vitamin K2; these studies are being paid for by traditional medical doctors who are treating diseased patients, and the only active is a vitamin,” Anderson said. “That’s what it really should be about: You have science, science leads to discovery, which in turn leads to an investment into proving that [an active] works as a dietary supplement.”

References:
Peeters FECM, et al. Calcific aortic valve stenosis: hard disease in the heart. Euro Heart J (2017) 0,1-8.
Knapen MHJ, et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis (2015) 19;113(5).

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Beef extract obtained from cooking process may boost exercise performance, mice study finds 

13 Nov 2018 --- An extract obtained by cooking beef could improve exercise performance and lessen post-exercise fatigue, a mice study published in Nutrients has found. The study sought to evaluate the potential beneficial effects of beef extract on exercise performance, as well as the related role of the gut microbiota. Although the extract was found to improve exercise performance by preserving muscle glycogen, it was independent of any relationship with the gut microbiota.

Food Ingredients News

Diabetes and cardiovascular disease top the list of health fears for older men, Lycored reveals

13 Nov 2018 --- Diabetes and cardiovascular disease are the most common health concerns for older men in the west, a new survey by wellness company Lycored has revealed. The research also indicates that  US men are more worried about heart disease than they are about cancer.

Health & Nutrition News

Conveying overall wellness: Better-for-you NPD thrives on protein, fiber and natural platforms

08 Nov 2018 --- With half of all food and beverage launches in 2018 year to date having a better-for-you claim, the surge in product innovation catering to consumer demands for a healthier lifestyle is clear-cut. But what are some of the standout strategies for creating products with a much sought after health halo? Yesterday’s webinar presented by Innova Market Insights cast a light on the role of protein, fiber and natural ingredients in providing formulators with key strategies to convey overall wellness in food and beverage development.

Health & Nutrition News

Cherry on top: Anthocyanin-rich foods linked to a healthier heart

08 Nov 2018 --- A new study has linked the consumption of anthocyanin-rich foods to a reduced risk of coronary heart disease and cardiovascular disease. Anthocyanins are red-pigmented flavonoids that give certain fruit and vegetables their rich red, purple and blue colors. They are found in berries, black soybean, black rice and cherries. 

Health & Nutrition News

World’s first celiac vaccine enters international Phase 2 trial

07 Nov 2018 --- The world's first vaccine for people who have celiac disease is to be rolled out in an international trial. If successful, the vaccine, Nexvax2, would be the first medicine of its kind for people with the disease. Currently, following a gluten-free diet is the only treatment, but even the most diligent patients can suffer the adverse effects of accidental exposure. Therefore, the results of the vaccine’s trial may be eagerly awaited by those avoiding gluten due to their celiac condition.

More Articles
URL : http://www.nutritioninsight.com:80/news/vitamin-k2-could-be-novel-therapeutic-target-for-common-cardiovascular-condition.html